These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 12710863)
1. Drug interactions with cholinesterase inhibitors. Defilippi JL; Crismon ML Drugs Aging; 2003; 20(6):437-44. PubMed ID: 12710863 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Crismon ML Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465 [TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. VanDenBerg CM; Kazmi Y; Jann MW Drugs Aging; 2000 Feb; 16(2):123-38. PubMed ID: 10755328 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. Imbimbo BP CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943 [TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713 [TBL] [Abstract][Full Text] [Related]
6. Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease. Bottiggi KA; Salazar JC; Yu L; Caban-Holt AM; Ryan M; Schmitt FA Am J Geriatr Psychiatry; 2007 Apr; 15(4):357-9. PubMed ID: 17384320 [No Abstract] [Full Text] [Related]
12. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Nordberg A; Svensson AL Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Jann MW; Shirley KL; Small GW Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759 [TBL] [Abstract][Full Text] [Related]
15. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Grossberg GT; Edwards KR; Zhao Q J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811 [TBL] [Abstract][Full Text] [Related]
16. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Schmidt BH; Heinig R Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230 [TBL] [Abstract][Full Text] [Related]
17. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141 [TBL] [Abstract][Full Text] [Related]
18. Donepezil use in Alzheimer disease. Barner EL; Gray SL Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825 [TBL] [Abstract][Full Text] [Related]
19. Advances in the pharmacotherapy of Alzheimer's disease. Gauthier S CMAJ; 2002 Mar; 166(5):616-23. PubMed ID: 11898943 [No Abstract] [Full Text] [Related]